Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Medicine UCSF Medical Center
Home

Main navigation

  • About Us
    • Administration
    • Calendar
    • History / Chiefs
  • Faculty
  • Education
    • Continuing Medical Education
    • Medical Students
    • Residents
    • Visiting Faculty
    • Mentoring
  • Fellowship
    • Program Overview
    • Program Tracks
      • Research Track
      • Clinician Educator Track
    • Program Subtracks
      • Antimicrobial Stewardship/Hospital Epidemiology and Infection Prevention Track
      • Transplant ID Track
      • HIV Track
      • Addiction Medicine Track
    • Clinical Experiences
    • Curriculum
    • CORE
    • Fellow Well-Being
    • Life in ID Fellowship
    • Current Fellows
    • Fellowship Application Process
    • Recent Graduates
  • Patient Care
    • For Patients
      • Dysplasia
      • HIV
      • Infectious Disease Clinic
      • Neuro
      • Transplant
  • Research
  • Giving

Breadcrumb

  1. People
  2. Henry Chambers, MD
Image of Henry Chambers, MD
  • Send an Email
  • +1 415 206-5437

1001 Potrero Ave, Rm 3400 UCSF Box 0811 BLDG 30 San Francisco, CA 94110

View UCSF Profile

Henry Chambers, MD

Professor Emeritus

Dr. Chambers clinical and research interests are antimicrobial drug resistance, staphylococcal infections, experimental therapeutics, and epidemiology and pathogenesis of disease caused by Staphylococcus aureus. He is editor for the Sanford Guide to Antimicrobial Therapy and he has over 200 original publications and textbook chapters in the areas of drug resistance, endocarditis, bacterial infections, and staphylococcal diseases.

Dr. Chambers received his BA from Centre College in Kentucky and is a graduate of the Vanderbilt University School of Medicine. He trained in Internal Medicine and Infectious Diseases at the University of California San Francisco. Dr. Chambers has been a member of the medical faculty of the UCSF since 1983 where he currently is Professor of Medicine, Medical Director of Clinical Research Services for CTSI. He is an editor for Antimicrobial Agents and Chemotherapy, a reviewer for numerous medical publications, a peer reviewer for NIH study sections.
Education
B.A., - , Centre College Kentucky
Residency, - School of Medicine, University of California, San Francisco
M.D., - School of Medicine, Vanderbilt University
Publications
  1. Turner NA, Hamasaki T, Doernberg SB, Lodise TP, King HA, Ghazaryan V, Cosgrove SE, Jenkins TC, Liu C, Sharma S, Zaharoff S, Wahid L, Renard VJ, Cook P, Raad I, Hachem R, Chaftari AM, Sims M, DeMarco C, Miller LG, McCarthy MW, Morse CG, Lucasti C, Forrest GN, Cherabuddi K, Polk C, Fazili T, Rupp ME, Thompson GR, Kim K, Strnad L, Schnee AE, McKinnell JA, Ramesh M, Silveira FP, McCarty TP, Lee TC, McDonald EG, Paolino K, Wiegand K, Wall A, Riccobene T, Patel R, Rappo U, Evans S, Chambers HF, Fowler VG, Holland TL, Antibacterial Resistance Leadership Group. Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial. 2025. PMID: 40802264


  2. Howard-Anderson J, Doernberg SB, Dixon D, Gopinath R, Rubin D, Kinamon T, Kim P, Collyar D, Cosgrove SE, Fowler VG, Chambers HF, Evans SR, Holland TL, King HA, Boucher HW. Interagency Collaboration for Patient-Centered Antibacterial Drug Development. 2025. PMID: 40794656


  3. Aravamuthan B, Fehlings D, Novak I, Fahey M, Fowler E, Kruer M, Chambers H. A description and a diagnostic framework: Synergy for practical cerebral palsy diagnosis and care. 2025. PMID: 40734216


  4. Jiang J, Komarow L, Hill C, Boutzoukas AE, Hanson B, Arias CA, Bonomo RA, Evans S, Doi Y, Satlin MJ, Weston G, Cober E, Valderrama-Beltran SL, Mendoza SS, Liu Z, Fries BC, Tambyah PA, Chambers HF, Fowler VG, van Duin D, Kreiswirth BN, Chen L. Molecular epidemiology and clinical characterization of carbapenemase-producing Enterobacter spp. from an international cohort. 2024. PMID: 39667036


  5. Chambers HF, Arias CA. Rifaximin Prophylaxis and "Collateral Damage" in Patients with Advanced Liver Disease. 2025. PMID: 40348034


  6. Belmont C, Inamdar P, Shariff-Marco S, Gul A, Huang AJ, Chambers HF, Raphael E. Spatial clusters of dominant lineages of uropathogenic Escherichia coli in a community dwelling patient population. 2025. PMID: 40386426


  7. Evans SR, Pennello G, Zhang S, Li Y, Wang Y, Cao Q, Komarow L, Hamasaki T, Petrides V, Meier K, Galicia NP, Fowler VG, Boucher HW, Doernberg SB, Banerjee R, Rigatto MH, Kreiswirth BN, Bonomo RA, Chambers HF, Patel R. Intention-to-diagnose and distinct research foci in diagnostic accuracy studies. 2025. PMID: 40158520


  8. Ersoy SC, Madrigal SL, Proctor RA, Chambers HF, Xiong YQ, Bayer AS. NaHCO3 modulates the bla operon and β-lactam susceptibility in borderline oxacillin-resistant Staphylococcus aureus (BORSA). 2024. PMID: 39704154


  9. Duis J, Agresta L, Bennett WE, Chambers H, Clarke A, Fairhurst C, Hoover-Fong J, Murphy F, Noritz G, Schwantes S, Shreve M, Thusang K, Weidemann D, Beale R, Mehta A, Wilhelmsen A, Summerfield N. International Expert Opinion on Standard of Care for Patients With Schinzel-Giedion Syndrome: A Modified Delphi Study. 2025. PMID: 39967563


  10. Minter DJ, Appa A, Chambers HF, Doernberg SB. The positioning of ceftobiprole in the treatment of Staphylococcus aureus bacteremia. 2024. PMID: 38466317


  11. Ersoy SC, Madrigal SL, Chen L, Mediavilla J, Kreiswirth B, Flores EA, Miller LG, Xiong YQ, Harrison EM, Blane B, Peacock SJ, Patel R, Chambers HF, Bayer AS, Proctor RA. Phenotypic and Genotypic Correlates of the NaHCO3-Responsive Phenotype Among Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates from Skin and Soft Tissue Infections (SSTIs). 2024. PMID: 39626860


  12. Chambers HF, Fowler VG. Intertwining clonality and resistance: Staphylococcus aureus in the antibiotic era. 2024. PMID: 39352382


  13. Wen SCH, Harris PNA, Forde B, Permana B, Chatfield MD, Lau CL, Spurling G, Bauer MJ, Balch R, Chambers H, Schlapbach LJ, Clark JE, Dougherty S, Blyth CC, Britton PN, Clifford V, Haeusler GM, McMullan B, Wadia U, Paterson DL, Irwin AD. Characterization of Gram-negative Bloodstream Infections in Hospitalized Australian Children and Their Clinical Outcomes. 2024. PMID: 38917034


  14. Yasmin M, Marshall SH, Chen L, Rhoads DD, Jacobs MR, Rojas LJ, Perez F, Hujer AM, Hujer KM, van Duin D, Fowler V, Chambers HF, Kreiswirth BN, Bonomo RA, Antibacterial Resistance Leadership Group. A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae. 2024. PMID: 39162528


  15. Kinamon T, Waack U, Needles M, Rubin D, Collyar D, Doernberg SB, Evans SR, Hamasaki T, Holland TL, Howard-Anderson J, Chambers H, Fowler VG, Nambiar S, Kim P, Boucher HW, Gopinath R. Exploration of a Potential DOOR Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs. 2024. PMID: 38527855


  16. Kwon J, Pelletiers W, Galloway Peña J, van Duin D, Ledbetter L, Baum K, Ruffin F, Knisely JM, Bizzell E, Fowler VG, Chambers HF, Pettigrew MM. Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000-2021. 2024. PMID: 38306502


  17. Chambers HF, Zhang S, Evans S. Duke Infective Endocarditis Criteria 3.0 for the Clinician: Defining What Is Possible. 2024. PMID: 38330224


  18. Lai L-Y, Satishkumar N, Cardozo S, Hemmadi V, Marques LB, Huang L, Filipe SR, Pinho MG, Chambers HF, Chatterjee SS. Altered PBP4 and GdpP functions synergistically mediate MRSA-like high-level, broad-spectrum β-lactam resistance in Staphylococcus aureus. 2024. PMID: 38530033


  19. Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J, Cober E, Alenazi T, Zong Z, Xie Q, Liu Z, Li L, Yu Y, Gao H, Kanj SS, Figueroa J, Herc E, Cordova E, Weston G, Ananth Tambyah P, Garcia-Diaz J, Kaye KS, Dhar S, Munita JM, Salata RA, Vilchez S, Stryjewski ME, Villegas Botero MV, Iovleva A, Evans SR, Baum K, Hill C, Kreiswirth BN, Patel R, Paterson DL, Arias CA, Bonomo RA, Chambers HF, Fowler VG, Satlin MJ, van Duin D, Doi Y, Multi-Drug Resistant Organism Network Investigators. Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions. 2024. PMID: 37738153


  20. Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, Kinamon T, Leister-Tebbe H, Hill C, Geres H, Holland TL, Doernberg SB, Chambers HF, Fowler VG, Evans SR, Boucher HW. Moving beyond mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. 2023. PMID: 37740559


  21. Ersoy SC, Proctor RA, Rose WE, Abdelhady W, Fan S-H, Madrigal SL, Elsayed AM, Chambers HF, Sobral RG, Bayer AS. Sensitizing methicillin-resistant Staphylococcus aureus (MRSA) to cefuroxime: the synergic effect of bicarbonate and the wall teichoic acid inhibitor ticlopidine. 2024. PMID: 38349162


  22. Iovleva A, McElheny CL, Fowler EL, Cober E, Herc ES, Arias CA, Hill C, Baum K, Fowler VG, Chambers HF, Greenwood-Quaintance KE, Patel R, van Duin D, Bonomo RA, Doi Y. In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. 2024. PMID: 38289078


  23. Minter DJ, Appa A, Chambers HF, Doernberg SB. Contemporary Management of Staphylococcus aureus Bacteremia-Controversies in Clinical Practice. 2023. PMID: 37950887


  24. Minter DJ, Appa A, Chambers HF, Doernberg SB. Executive Summary: State-of-The-Art Review: Contemporary Management of Staphylococcus aureus Bacteremia: Controversies in Clinical Practice. 2023. PMID: 38031168


  25. Lai LY, Satishkumar N, Cardozo S, Hemmadi V, Marques LB, Huang L, Filipe SR, Pinho MG, Chambers HF, Chatterjee SS. Altered PBP4 and GdpP functions synergistically mediate MRSA-like high-level, broad-spectrum β-lactam resistance in Staphylococcus aureus. 2023. PMID: 37961375


  26. Raphael E, Inamdar PP, Belmont C, Shariff-Marco S, Huang AJ, Chambers HF. Spatial clusters of extended-spectrum beta-lactamase-producing Escherichia coli causing community-onset bacteriuria due to repeat infections: cluster analysis from a large urban medical center, San Francisco, 2014-2020. 2023. PMID: 37858209


  27. Chambers HF, Cross HR, Souli M, Evans SR, Patel R, Fowler VG, Antibacterial Resistance Leadership Group. The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions. 2023. PMID: 37843121


  28. Evans SR, Patel R, Hamasaki T, Howard-Anderson J, Kinamon T, King HA, Collyar D, Cross HR, Chambers HF, Fowler VG, Boucher HW, Antibacterial Resistance Leadership Group. The Future Ain't What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations. 2023. PMID: 37843122


  29. Cross HR, Greenwood-Quaintance KE, Souli M, Komarow L, Geres HS, Hamasaki T, Chambers HF, Fowler VG, Evans SR, Patel R, Antibacterial Resistance Leadership Group. Under the Hood: The Scientific Leadership, Clinical Operations, Statistical and Data Management, and Laboratory Centers of the Antibacterial Resistance Leadership Group. 2023. PMID: 37843120


  30. Rouphael N, Winokur P, Keefer MC, Traenkner J, Drobeniuc A, Doi Y, Munsiff S, Fowler VG, Evans S, Oler RE, Tuyishimire B, Lee M, Ghazaryan V, Chambers HF, DMID 15-0045 study group. Daily fosfomycin versus levofloxacin for complicated urinary tract infections. 2023. PMID: 37698412


  31. Kinamon T, Gopinath R, Waack U, Needles M, Rubin D, Collyar D, Doernberg SB, Evans S, Hamasaki T, Holland TL, Howard-Anderson J, Chambers H, Fowler VG, Nambiar S, Kim P, Boucher HW. Exploration of a Potential DOOR Endpoint for Complicated Intra-Abdominal Infections Using Nine Registrational Trials for Antibacterial Drugs. 2023. PMID: 37073571


  32. Boutzoukas AE, Komarow L, Chen L, Hanson B, Kanj SS, Liu Z, Salcedo Mendoza S, Ordoñez K, Wang M, Paterson DL, Evans S, Ge L, Giri A, Hill C, Baum K, Bonomo RA, Kreiswirth B, Patel R, Arias CA, Chambers HF, Fowler VG, van Duin D, Multi-Drug Resistant Organism Network Investigators. International Epidemiology of Carbapenemase-Producing Escherichia coli. 2023. PMID: 37154071


  33. Raphael E, Inamdar PP, Belmont C, Shariff-Marco S, Huang A, Chambers H. Spatial clusters of extended-spectrum beta-lactamase-producing Escherichia coli causing community-onset bacteriuria due to repeat infections: cluster analysis from a large urban medical center, San Francisco, 2014-2020. 2023. PMID: 37292942


  34. Fan SH, Proctor RA, Ersoy SC, Manna AC, Cheung AL, Götz F, Chambers HF, Bayer AS. Role of the NaHCO3 Transporter MpsABC in the NaHCO3-β-Lactam-Responsive Phenotype in Methicillin-Resistant Staphylococcus aureus. 2023. PMID: 37102972


  35. Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, Herc E, Alenazi T, Kaye KS, Garcia-Diaz J, Li L, Kanj SS, Liu Z, Oñate JM, Salata RA, Marimuthu K, Gao H, Zong Z, Valderrama-Beltrán SL, Yu Y, Tambyah P, Weston G, Salcedo S, Abbo LM, Xie Q, Ordoñez K, Wang M, Stryjewski ME, Munita JM, Paterson DL, Evans S, Hill C, Baum K, Bonomo RA, Kreiswirth BN, Villegas MV, Patel R, Arias CA, Chambers HF, Fowler VG, Doi Y, van Duin D, Satlin MJ, Antibacterial Resistance Leadership Group and Multi-Drug Resistant Organism Network Investigators. Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study. 2023. PMID: 36774938


  36. Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, Kinamon T, Hill C, Gelone SP, Mariano D, Baba T, Holland TL, Doernberg SB, Chambers HF, Fowler VG, Evans SR, Boucher HW. Improving Traditional Registrational Trial Endpoints: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Complicated Urinary Tract Infection Clinical Trials. 2022. PMID: 36031403


  37. Alexander JAN, Worrall LJ, Hu J, Vuckovic M, Satishkumar N, Poon R, Sobhanifar S, Rosell FI, Jenkins J, Chiang D, Mosimann WA, Chambers HF, Paetzel M, Chatterjee SS, Strynadka NCJ. Structural basis of broad-spectrum �-lactam resistance in Staphylococcus aureus. 2023. PMID: 36599987


  38. Tamma PD, Souli M, Billard M, Campbell J, Conrad D, Ellison DW, Evans B, Evans SR, Greenwood-Quaintance KE, Filippov AA, Geres HS, Hamasaki T, Komarow L, Nikolich MP, Lodise TP, Nayak SU, Norice-Tra C, Patel R, Pride D, Russell J, Van Tyne D, Chambers HF, FowlerJr VG, Schooley RT, Antibacterial Resistance Leadership Group. Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial. 2022. PMID: 36578069


  39. Lodise TP, O'Donnell JN, Balevic S, Liu X, Gu K, George J, Raja S, Guptill JT, Zaharoff S, Schwager N, Fowler VG, Wall A, Wiegand K, Chambers HF, Antibacterial Resistance Leadership Group. Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults. 2022. PMID: 36394326


  40. Lodise TP, O'Donnell JN, Raja S, Guptill JT, Zaharoff S, Schwager N, Fowler VG, Beresnev T, Wall A, Wiegand K, Serti Chrisos E, Balevic S, Chambers HF, Antibacterial Resistance Leadership Group. Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers. 2022. PMID: 36394316


  41. Ersoy SC, Gon?alves B, Cavaco G, Manna AC, Sobral RG, Nast CC, Proctor RA, Chambers HF, Cheung A, Bayer AS. Influence of Sodium Bicarbonate on Wall Teichoic Acid Synthesis and �-Lactam Sensitization in NaHCO3-Responsive and Nonresponsive Methicillin-Resistant Staphylococcus aureus. 2022. PMID: 36377886


  42. Tamma PD, Komarow L, Ge L, Garcia-Diaz J, Herc ES, Doi Y, Arias CA, Albin O, Saade E, Miller LG, Jacob JT, Satlin MJ, Krsak M, Huskins WC, Dhar S, Shelburne SA, Hill C, Baum KR, Bhojani M, Greenwood-Quaintance KE, Schmidt-Malan SM, Patel R, Evans SR, Chambers HF, Fowler VG, van Duin D, Antibacterial Resistance Leadership Group. Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study. 2022. PMID: 36381622


  43. Chambers HF, Fowler VG, Antibacterial Resistance Leadership Group. Confronting antimicrobial resistance together. 2022. PMID: 36193938


  44. Kwon J, Kong Y, Wade M, Williams DJ, Creech CB, Evans S, Walter EB, Martin JM, Gerber JS, Newland JG, Hofto ME, Staat MA, Chambers HF, Fowler VG, Huskins WC, Pettigrew MM. Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia. 2022. PMID: 35249113


  45. Ersoy SC, Manna AC, Proctor RA, Chambers HF, Harrison EM, Bayer AS, Cheung A. The NaHCO3-Responsive Phenotype in Methicillin-Resistant Staphylococcus aureus (MRSA) Is Influenced by mecA Genotype. 2022. PMID: 35575577


  46. Howard-Anderson J, Dai W, Yahav D, Hamasaki T, Turjeman A, Koppel F, Franceschini E, Hill C, Sund Z, Chambers HF, Fowler VG, Boucher HW, Evans SR, Paul M, Holland TL, Doernberg SB. A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection. 2022. PMID: 35615299


  47. Shore BJ, McCarthy J, Shrader MW, Graham HK, Veerkamp M, Rutz E, Chambers H, Davids JR, Narayanan U, Novacheck TF, Pierz K, Dreher T, Rhodes J, Shilt J, Theologis T, Van Campenhout A, Kay RM. Anterior distal femoral hemiepiphysiodesis in children with cerebral palsy: Establishing surgical indications and techniques using the modified Delphi method and literature review. 2022. PMID: 35615394


  48. Kay RM, McCarthy J, Narayanan U, Rhodes J, Rutz E, Shilt J, Shore BJ, Veerkamp M, Shrader MW, Theologis T, Van Campenhout A, Pierz K, Chambers H, Davids JR, Dreher T, Novacheck TF, Graham K. Finding consensus for hamstring surgery in ambulatory children with cerebral palsy using the Delphi method. 2022. PMID: 35615393


  49. Shropshire WC, Dinh AQ, Earley M, Komarow L, Panesso D, Rydell K, Gómez-Villegas SI, Miao H, Hill C, Chen L, Patel R, Fries BC, Abbo L, Cober E, Revolinski S, Luterbach CL, Chambers H, Fowler VG, Bonomo RA, Shelburne SA, Kreiswirth BN, van Duin D, Hanson BM, Arias CA. Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX. 2022. PMID: 35357213


  50. Ersoy SC, Chan LC, Yeaman MR, Chambers HF, Proctor RA, Ludwig KC, Schneider T, Manna AC, Cheung A, Bayer AS. Impacts of NaHCO3 on β-Lactam Binding to PBP2a Protein Variants Associated with the NaHCO3-Responsive versus NaHCO3-Non-Responsive Phenotypes. 2022. PMID: 35453214


  51. Williams DJ, Creech CB, Walter EB, Martin JM, Gerber JS, Newland JG, Howard L, Hofto ME, Staat MA, Oler RE, Tuyishimire B, Conrad TM, Lee MS, Ghazaryan V, Pettigrew MM, Fowler VG, Chambers HF, Zaoutis TE, Evans S, Huskins WC, The DMID 14-0079 Study Team. Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial. 2022. PMID: 35040920


  52. Appa A, Adamo M, Le S, Davis J, Winston L, Doernberg SB, Chambers H, Martin M, Hills NK, Coffin PO, Jain V. Comparative one-year outcomes of invasive Staphylococcus aureus infections among persons with and without drug use: an observational cohort study. 2021. PMID: 33904900


  53. Lodise TP, Scheetz M, Carreno JJ, Chambers H, Fowler V, Holland TL. Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. 2022. PMID: 35079599


  54. Poon R, Basuino L, Satishkumar N, Chatterjee A, Mukkayyan N, Buggeln E, Huang L, Nair V, Argudín MA, Datta SK, Chambers HF, Chatterjee SS. Loss of GdpP function in Staphylococcus aureus leads to β-lactam tolerance and enhanced evolution of β-lactam resistance. 2021. PMID: 34843389


  55. Wang M, Earley M, Chen L, Hanson BM, Yu Y, Liu Z, Salcedo S, Cober E, Li L, Kanj SS, Gao H, Munita JM, Ordoñez K, Weston G, Satlin MJ, Valderrama-Beltrán SL, Marimuthu K, Stryjewski ME, Komarow L, Luterbach C, Marshall SH, Rudin SD, Manca C, Paterson DL, Reyes J, Villegas MV, Evans S, Hill C, Arias R, Baum K, Fries BC, Doi Y, Patel R, Kreiswirth BN, Bonomo RA, Chambers HF, Fowler VG, Arias CA, van Duin D, Multi-Drug Resistant Organism Network Investigators. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. 2021. PMID: 34767753


  56. Ersoy SC, Hanson BM, Proctor RA, Arias CA, Tran TT, Chambers HF, Bayer AS. Impact of Bicarbonate-β-Lactam Exposures on Methicillin-Resistant Staphylococcus aureus (MRSA) Gene Expression in Bicarbonate-β-Lactam-Responsive vs. Non-Responsive Strains. 2021. PMID: 34828256


  57. Chowdhury J, Patel R, Chambers H. Oral versus Intravenous Antibiotics for Endocarditis. 2021. PMID: 34525290


  58. Ersoy SC, Rose WE, Patel R, Proctor RA, Chambers HF, Harrison EM, Pak Y, Bayer AS. A Combined Phenotypic-Genotypic Predictive Algorithm for In Vitro Detection of Bicarbonate: β-Lactam Sensitization among Methicillin-Resistant Staphylococcus aureus (MRSA). 2021. PMID: 34572671


  59. Appa A, Adamo M, Le S, Davis J, Winston L, Doernberg SB, Chambers H, Martin M, Hills NK, Coffin P, Jain V. Patient-Directed Discharges Among Persons Who Use Drugs Hospitalized with Invasive S. aureus Infections: Opportunities for Improvement. 2021. PMID: 34508704


  60. Chambers HF, Evans SR, Patel R, Cross HR, Harris AD, Doi Y, Boucher HW, van Duin D, Tsalik EL, Holland TL, Pettigrew MM, Tamma PD, Hodges KR, Souli M, Fowler VG. Antibacterial Resistance Leadership Group 2.0 - Back to Business. 2021. PMID: 33588438


  61. Raphael E, Glymour MM, Chambers HF. Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system. 2021. PMID: 34380549


  62. Kay RM, Pierz K, McCarthy J, Graham HK, Chambers H, Davids JR, Narayanan U, Novacheck TF, Rhodes J, Rutz E, Shilt J, Shore BJ, Veerkamp M, Shrader MW, Theologis T, Van Campenhout A, Dreher T. Distal rectus femoris surgery in children with cerebral palsy: results of a Delphi consensus project. 2021. PMID: 34211604


  63. Bayer AS, Chambers HF. Prosthetic Valve Endocarditis Diagnosis and Management- New Paradigm Shift Narratives. 2021. PMID: 33458755


  64. Ersoy SC, Chambers HF, Proctor RA, Rosato AE, Mishra NN, Xiong YQ, Bayer AS. Impact of Bicarbonate on PBP2a Production, Maturation, and Functionality in Methicillin-Resistant Staphylococcus aureus (MRSA). 2021. PMID: 33649115


  65. Chambers HF. Skin and Soft Tissue Infections. 2021. PMID: 33494875


  66. Spinelli MA, Glidden DV, Gennatas ED, Bielecki M, Beyrer C, Rutherford G, Chambers H, Goosby E, Gandhi M. Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity. 2021. PMID: 33631099


  67. Chambers HF. Skin and Soft Tissue Infections in Persons Who Inject Drugs. 2020. PMID: 33303334


  68. Doernberg SB, Komarow L, Tran TTT, Sund Z, Pandori MW, Jensen D, Tsalik EL, Deal CD, Chambers HF, Fowler VG, Evans SR, Patel R, Klausner JD. Simultaneous Evaluation of Diagnostic Assays for Pharyngeal and Rectal Neisseria gonorrhoeae and Chlamydia trachomatis Using a Master Protocol. 2020. PMID: 31734695


  69. Rutz E, McCarthy J, Shore BJ, Shrader MW, Veerkamp M, Chambers H, Davids JR, Kay RM, Narayanan U, Novacheck TF, Pierz K, Rhodes J, Shilt J, Theologis T, Van Campenhout A, Dreher T, Graham K. Indications for gastrocsoleus lengthening in ambulatory children with cerebral palsy: a Delphi consensus study. 2020. PMID: 33204348


  70. Chambers HF. Rifabutin to the Rescue? 2020. PMID: 32914842


  71. Lodise TP, Smith NM, O'Donnell N, Eakin AE, Holden PN, Boissonneault KR, Zhou J, Tao X, Bulitta JB, Fowler VG, Chambers HF, Bonomo RA, Tsuji BT. Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. 2020. PMID: 32464664


  72. Chambers HF, Bayer AS. Native-Valve Infective Endocarditis. 2020. PMID: 32757525


  73. Raphael E, Chambers HF. Differential Trends in Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Infections in Four Health Care Facilities in a Single Metropolitan Area: A Retrospective Analysis. 2020. PMID: 32589493


  74. Alexander JAN, Radaeva M, King DT, Chambers HF, Cherkasov A, Chatterjee SS, Strynadka NCJ. -Structural analysis of avibactam-mediated activation of the bla and mec divergons in methicillin-resistant Staphylococcus aureus. 2020. PMID: 32518158


  75. Spellberg B, Chambers HF, Musher DM, Walsh TL, Bayer AS. Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis: A Narrative Review. 2020. PMID: 32227127


  76. Ersoy SC, Otmishi M, Milan VT, Li L, Pak Y, Mediavilla J, Chen L, Kreiswirth B, Chambers HF, Proctor RA, Xiong YQ, Fowler VG, Bayer AS. Scope and Predictive Genetic/Phenotypic Signatures of 'Bicarbonate [NaHCO3]-Responsiveness' and ß-Lactam Sensitization Among Methicillin-Resistant Staphylococcus aureus (MRSA). 2020. PMID: 32041719


  77. Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, Schrank J, Bleasdale SC, Schultz S, Barron M, Stapleton A, Wray D, Chambers H, Fowler VG, Holland TL. The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). 2020. PMID: 31157370


  78. Adamson PC, Pandori MW, Doernberg SB, Komarow L, Sund Z, Tran TTT, Jensen D, Tsalik EL, Deal CD, Chambers HF, Fowler VG, Evans SR, Patel R, Klausner JD. Analytical evaluation of the Abbott RealTime CT/NG Assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in rectal and pharyngeal swabs. 2020. PMID: 32247863


  79. van Duin D, Arias CA, Komarow L, Chen L, Hanson BM, Weston G, Cober E, Garner OB, Jacob JT, Satlin MJ, Fries BC, Garcia-Diaz J, Doi Y, Dhar S, Kaye KS, Earley M, Hujer AM, Hujer KM, Domitrovic TN, Shropshire WC, Dinh A, Manca C, Luterbach CL, Wang M, Paterson DL, Banerjee R, Patel R, Evans S, Hill C, Arias R, Chambers HF, Fowler VG, Kreiswirth BN, Bonomo RA. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. 2020. PMID: 32151332


  80. Rose WE, Bienvenida AM, Xiong YQ, Chambers HF, Bayer AS, Ersoy SC. Ability of Bicarbonate Supplementation to Sensitize Selected Methicillin-Resistant Staphylococcus aureus (MRSA) Strains to ß-Lactam Antibiotics in an Ex Vivo Simulated Endocardial Vegetation Model. 2019. PMID: 31844004


  81. Volberding P, Chambers HF. Antimicrobial Drug Development Efficiency and Surrogate Markers of Clinical Benefit. 2019. PMID: 31710332


  82. Kalil AC, Holubar M, Deresinski S, Chambers HF. Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia? 2019. PMID: 31640977


  83. Liu C, Strnad L, Beekmann SE, Polgreen PM, Chambers HF. Clinical Practice Variation Among Adult Infectious Disease Physicians in the Management of Staphylococcus aureus Bacteremia. 2019. PMID: 30601989


  84. Pulgar S, Bains S, Gooch J, Chambers H, Noritz GH, Wright E, Sawhney TG, Pyenson B, Ferro C. Prevalence, Patterns, and Cost of Care for Children with Cerebral Palsy Enrolled in Medicaid Managed Care. 2019. PMID: 31232210


  85. Ersoy SC, Abdelhady W, Li L, Chambers HF, Xiong YQ, Bayer AS. Bicarbonate Resensitization of Methicillin-Resistant Staphylococcus aureus to ß-Lactam Antibiotics. 2019. PMID: 31010857


  86. Evans SR, Tran TTT, Hujer AM, Hill CB, Hujer KM, Mediavilla JR, Manca C, Domitrovic TN, Perez F, Farmer M, Pitzer KM, Wilson BM, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Fowler VG, Chambers HF, Bonomo RA, Antibacterial Resistance Leadership Group (ARLG). Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV. 2019. PMID: 30239599


  87. Evans SR, Follmann D, Liu Y, Holland T, Doernberg SB, Rouphael N, Hamasaki T, Jiang Y, Lok JJ, Tran TTT, Harris AD, Fowler VG, Boucher H, Kreiswirth BN, Bonomo RA, Van Duin D, Paterson DL, Chambers H. Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS). 2019. PMID: 30351426


  88. Doernberg SB, Tran TTT, Tong SYC, Paul M, Yahav D, Davis JS, Leibovici L, Boucher HW, Corey GR, Cosgrove SE, Chambers HF, Fowler VG, Evans SR, Holland TL. Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection. 2018. PMID: 30321315


  89. Guimaraes AO, Cao Y, Hong K, Mayba O, Peck M, Gutierrez J, Ruffin F, Carrasco-Triguero M, Dinoso JB, Clemenzi-Allen A, Koss CA, Maskarinec S, Chambers HF, Fowler VG, Baruch A, Rosenberger CM. A prognostic model of persistent bacteremia and mortality in complicated S. aureus bloodstream infection. 2018. PMID: 30165412


  90. Gutierrez J, Guimaraes AO, Lewin-Koh N, Berhanu A, Xu M, Cao Y, Kim J, Yan D, Chang JK, Dinoso JB, Koss CA, Clemenzi-Allen A, Chambers HF, Peck MC, Baruch A, Rosenberger CM. Sustained Circulating Bacterial Deoxyribonucleic Acid Is Associated With Complicated Staphylococcus aureus Bacteremia. 2019. PMID: 31024970


  91. Holland TL, Chambers HF, Boucher HW, Corey GR, Coleman R, Castaneda-Ruiz B, Fowler VG. Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults. 2019. PMID: 30202941


  92. Chambers HF. Omadacycline - The Newest Tetracycline. 2019. PMID: 30726683


  93. Alexander JAN, Chatterjee SS, Hamilton SM, Eltis LD, Chambers HF, Strynadka NCJ. Structural and kinetic analysis of penicillin-binding protein 4 (PBP4)-mediated antibiotic resistance in Staphylococcus aureus. 2018. PMID: 30366985


  94. Doernberg SB, Abbo LM, Burdette SD, Fishman NO, Goodman EL, Kravitz GR, Leggett JE, Moehring RW, Newland JG, Robinson PA, Spivak ES, Tamma PD, Chambers HF. Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting. 2018. PMID: 29590355


  95. da Costa TM, de Oliveira CR, Chambers HF, Chatterjee SS. PBP4: A New Perspective on Staphylococcus aureus ß-Lactam Resistance. 2018. PMID: 29932109


  96. Basuino L, Jousselin A, Alexander JAN, Strynadka NCJ, Pinho MG, Chambers HF, Chatterjee SS. PBP4 activity and its overexpression are necessary for PBP4-mediated high-level ß-lactam resistance. 2018. PMID: 29360990


  97. Bystritsky R, Chambers H. Cellulitis and Soft Tissue Infections. Volume 168 of Issue 3. 2018. PMID: 29404597


  98. Daum RS, Kumar N, Chambers HF. A Trial of Antibiotics for Smaller Skin Abscesses. 2017. PMID: 29281570


  99. Bowen AC, Carapetis JR, Currie BJ, Fowler V, Chambers HF, Tong SYC. Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess. 2017. PMID: 29255730


  100. Chatterjee SS, Chen L, Gilbert A, da Costa TM, Nair V, Datta SK, Kreiswirth BN, Chambers HF. PBP4 Mediates ß-Lactam Resistance by Altered Function. 2017. PMID: 28807923


  101. Katayama Y, Azechi T, Miyazaki M, Takata T, Sekine M, Matsui H, Hanaki H, Yahara K, Sasano H, Asakura K, Takaku T, Ochiai T, Komatsu N, Chambers HF. Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus. 2017. PMID: 28827421


  102. Woodworth MH, Marquez C, Chambers H, Luetkemeyer A. Disabling Dactylitis and Tenosynovitis Due to Mycobacterium haemophilum in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome. 2017. PMID: 28959701


  103. Doernberg SB, Chambers HF. Antimicrobial Stewardship Approaches in the Intensive Care Unit. 2017. PMID: 28687210


  104. Daum RS, Miller LG, Immergluck L, Fritz S, Creech CB, Young D, Kumar N, Downing M, Pettibone S, Hoagland R, Eells SJ, Boyle MG, Parker TC, Chambers HF. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. 2017. PMID: 28657870


  105. Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, Manca C, Tran TTT, Domitrovic TN, Higgins PG, Seifert H, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall T, Marzan C, Fowler VG, Chambers HF, Bonomo RA. Correction for Evans et al., "Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III". 2017. PMID: 28536161


  106. Hamilton SM, Alexander JAN, Choo EJ, Basuino L, da Costa TM, Severin A, Chung M, Aedo S, Strynadka NCJ, Tomasz A, Chatterjee SS, Chambers HF. High-Level Resistance of Staphylococcus aureus to ß-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4). 2017. PMID: 28373193


  107. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. Can Ceftazidime-Avibactam and Aztreonam Overcome ß-Lactam Resistance Conferred by Metallo-ß-Lactamases in Enterobacteriaceae? 2017. PMID: 28167541


  108. Chambers HF, Cross HR, Evans SR, Kreiswirth BN, Fowler VG. The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress. 2017. PMID: 28350896


  109. Cross HR, Harris A, Arias RM, Chambers HF, Fowler VG. Transforming Concepts Into Clinical Trials and Creating a Multisite Network: The Leadership and Operations Center of the Antibacterial Resistance Leadership Group. 2017. PMID: 28350897


  110. Nigo M, Diaz L, Carvajal LP, Tran TT, Rios R, Panesso D, Garavito JD, Miller WR, Wanger A, Weinstock G, Munita JM, Arias CA, Chambers HF. Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis. 2017. PMID: 28232309


  111. Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, Manca C, Tran TT, Domitrovic TN, Higgins PG, Seifert H, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall T, Marzan C, Fowler VG, Chambers HF, Bonomo RA. Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III. 2016. PMID: 27795336


  112. Choo EJ, Chambers HF. Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. 2016. PMID: 28032484


  113. Diep BA, Le VT, Badiou C, Le HN, Pinheiro MG, Duong AH, Wang X, Dip EC, Aguiar-Alves F, Basuino L, Marbach H, Mai TT, Sarda MN, Kajikawa O, Matute-Bello G, Tkaczyk C, Rasigade JP, Sellman BR, Chambers HF, Lina G. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Volume 8 of Issue 357. 2016. PMID: 27655850


  114. Baxi SM, Clemenzi-Allen A, Gahbauer A, Deck D, Imp B, Vittinghoff E, Chambers HF, Doernberg S. Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia. 2016. PMID: 27324762


  115. Pollett S, Baxi SM, Rutherford GW, Doernberg SB, Bacchetti P, Chambers HF. Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center. 2016. PMID: 27216053


  116. Chambers HF, Basuino L, Hamilton SM, Choo EJ, Moise P. Daptomycin-ß-Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Endocarditis. 2016. PMID: 27090173


  117. Chan LC, Gilbert A, Basuino L, da Costa TM, Hamilton SM, Dos Santos KR, Chambers HF, Chatterjee SS. PBP 4 Mediates High-Level Resistance to New-Generation Cephalosporins in Staphylococcus aureus. 2016. PMID: 27067335


  118. Evans S, Kreiswirth B, Fowler V, Chambers H, Patel R, Hujer AM, Perez F, Bonomo RA. Reply to Lesho and Clifford. 2016. PMID: 27225238


  119. Spellberg B, Srinivasan A, Chambers HF. New Societal Approaches to Empowering Antibiotic Stewardship. 2016. PMID: 26914942


  120. Greninger AL, Chatterjee SS, Chan LC, Hamilton SM, Chambers HF, Chiu CY. Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance. Volume 11 of Issue 2. 2016. PMID: 26890675


  121. Evans S, Follmann D, Schoenfeld D, Fowler VG, Chambers HF. Reply to Phillips, Morris, and Walker. 2015. PMID: 26658301


  122. Evans SR, Hujer AM, Jiang H, Hujer KM, Hall T, Marzan C, Jacobs MR, Sampath R, Ecker DJ, Manca C, Chavda K, Zhang P, Fernandez H, Chen L, Mediavilla JR, Hill CB, Perez F, Caliendo AM, Fowler VG, Chambers HF, Kreiswirth BN, Bonomo RA, Antibacterial Resistance Leadership Group. Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. 2015. PMID: 26409063


  123. Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D, Chuang-Stein C, Cosgrove SE, Fowler VG, Lautenbach E, Chambers HF. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). 2015. PMID: 26113652


  124. Miller LG, Daum RS, Chambers HF. Antibacterial Treatment for Uncomplicated Skin Infections. 2015. PMID: 26083210


  125. Boyle-Vavra S, Li X, Alam MT, Read TD, Sieth J, Cywes-Bentley C, Dobbins G, David MZ, Kumar N, Eells SJ, Miller LG, Boxrud DJ, Chambers HF, Lynfield R, Lee JC, Daum RS. USA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus. 2015. PMID: 25852165


  126. Chan LC, Basuino L, Dip EC, Chambers HF. Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. 2015. PMID: 25801564


  127. Miller LG, Daum RS, Creech CB, Young D, Downing MD, Eells SJ, Pettibone S, Hoagland RJ, Chambers HF. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. 2015. PMID: 25785967


  128. Chan LC, Basuino L, Diep B, Hamilton S, Chatterjee SS, Chambers HF. Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus. Volume 59 of Issue 5. 2015. PMID: 25753637


  129. Chambers HF. Probability of eradication using vancomycin alone or in combination for methicillin-resistant Staphylococcus aureus bacteremia. 2014. PMID: 25392536


  130. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC,. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. 2014. PMID: 24973422


  131. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. 2014. PMID: 24947530


  132. Chambers HF. Pharmacology and the treatment of complicated skin and skin-structure infections. 2014. PMID: 24897088


  133. David MZ, Daum RS, Bayer AS, Chambers HF, Fowler VG, Miller LG, Ostrowsky B, Baesa A, Boyle-Vavra S, Eells SJ, Garcia-Houchins S, Gialanella P, Macias-Gil R, Rude TH, Ruffin F, Sieth JJ, Volinski J, Spellberg B. Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008-2011: significant geographic variation in community-onset infections. 2014. PMID: 24879783


  134. Date SV, Modrusan Z, Lawrence M, Morisaki JH, Toy K, Shah IM, Kim J, Park S, Xu M, Basuino L, Chan L, Zeitschel D, Chambers HF, Tan MW, Brown EJ, Diep BA, Hazenbos WL. Global gene expression of methicillin-resistant Staphylococcus aureus USA300 during human and mouse infection. Volume 209 of Issue 10. 2013. PMID: 24286981


  135. Diep BA, Afasizheva A, Le HN, Kajikawa O, Matute-Bello G, Tkaczyk C, Sellman B, Badiou C, Lina G, Chambers HF. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. Volume 208 of Issue 1. 2013. PMID: 23532096


  136. Hsiang MS, Shiau R, Nadle J, Chan L, Lee B, Chambers HF, Pan E. Epidemiologic Similarities in Pediatric Community-Associated Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus in the San Francisco Bay Area. 2012. PMID: 23687577


  137. Tattevin P, Schwartz BS, Graber CJ, Volinski J, Bhukhen A, Bhukhen A, Mai TT, Vo NH, Dang DN, Phan TH, Basuino L, Perdreau-Remington F, Chambers HF, Diep BA. Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus. Volume 55 of Issue 6. 2012. PMID: 22670044


  138. Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? 2012. PMID: 22563022


  139. Gardete S, Kim C, Hartmann BM, Mwangi M, Roux CM, Dunman PM, Chambers HF, Tomasz A. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. 2012. PMID: 22319446


  140. Graber CJ, Shane AL, Weintrub P, Chambers HF. Clonality of Staphylococcus aureus colonization over time in attendees of a camp for children with chronic dermatoses. 2011. PMID: 21895757


  141. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. 2011. PMID: 21217178


  142. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. 2011. PMID: 21208910


  143. Banerjee R, Gretes M, Harlem C, Basuino L, Chambers HF. A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level ß-lactam resistance contains mutations in three genes. 2010. PMID: 20805396


  144. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, Gardner DJ, Fan X, Tseng CW, Liu GY, Badiou C, Etienne J, Lina G, Matthay MA, DeLeo FR, Chambers HF. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Volume 107 of Issue 12. 2010. PMID: 20231457


  145. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated meticillin-resistant Staphylococcus aureus. 2010. PMID: 20206987


  146. Mendes RE, Sader HS, Deshpande LM, Diep BA, Chambers HF, Jones RN. Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid. Volume 48 of Issue 2. 2009. PMID: 19940054


  147. Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. 2009. PMID: 19917746


  148. DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. 2009. PMID: 19729844


  149. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. 2009. PMID: 19680247


  150. Winston L, Chambers H. Coming home with MRSA. 2009. PMID: 19667300


  151. Schwartz BS, Graber CJ, Diep BA, Basuino L, Perdreau-Remington F, Chambers HF. Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300. Volume 48 of Issue 10. 2009. PMID: 19374563


  152. Tattevin P, Basuino L, Chambers HF. Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response. 2009. PMID: 19366630


  153. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR, Chambers HF, Lu Y, Otto M. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Volume 106 of Issue 14. 2009. PMID: 19293374


  154. Cosgrove SE, Vigliani GA, Fowler VG, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. 2009. PMID: 19207079


  155. Chambers HF, Basuino L, Diep BA, Steenbergen J, Zhang S, Tattevin P, Alder J. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis. 2009. PMID: 19171803


  156. Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic. Volume 49 of Issue 2. 2008. PMID: 18820536


  157. Diep BA, Palazzolo-Ballance AM, Tattevin P, Basuino L, Braughton KR, Whitney AR, Chen L, Kreiswirth BN, Otto M, DeLeo FR, Chambers HF. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. Volume 3 of Issue 9. 2008. PMID: 18787708


  158. Chambers HF, Moellering RC, Kamitsuka P. Clinical decisions. Management of skin and soft-tissue infection. 2008. PMID: 18768953


  159. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. 2008. PMID: 18663172


  160. Liu C, Graber CJ, Karr M, Diep BA, Basuino L, Schwartz BS, Enright MC, O'Hanlon SJ, Thomas JC, Perdreau-Remington F, Gordon S, Gunthorpe H, Jacobs R, Jensen P, Leoung G, Rumack JS, Chambers HF. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Volume 46 of Issue 11. 2008. PMID: 18433335


  161. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. 2008. PMID: 18462092


  162. Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, des Etages SA, Jones A, Palazzolo-Ballance AM, Perdreau-Remington F, Sensabaugh GF, DeLeo FR, Chambers HF. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. Volume 197 of Issue 11. 2008. PMID: 18700257


  163. Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. 2008. PMID: 18378703


  164. David MZ, Siegel JD, Chambers HF, Daum RS. Determining whether methicillin-resistant Staphylococcus aureus is associated with health care. 2008. PMID: 18252879


  165. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Volume 148 of Issue 4. 2008. PMID: 18283202


  166. Rajendran PM, Young D, Maurer T, Chambers H, Perdreau-Remington F, Ro P, Harris H. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. 2007. PMID: 17846141


  167. Chambers HF, Hegde SS. Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin? 2007. PMID: 17547497


  168. Mitchell J, Siboo IR, Takamatsu D, Chambers HF, Sullam PM. Mechanism of cell surface expression of the Streptococcus mitis platelet binding proteins PblA and PblB. Volume 64 of Issue 3. 2007. PMID: 17462028


  169. Graber CJ, Wong MK, Carleton HA, Perdreau-Remington F, Haller BL, Chambers HF. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Volume 13 of Issue 3. 2007. PMID: 17552110


  170. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. 2006. PMID: 16914701


  171. Rutar T, Chambers HF, Crawford JB, Perdreau-Remington F, Zwick OM, Karr M, Diehn JJ, Cockerham KP. Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant Staphylococcus aureus. 2006. PMID: 16766029


  172. Seeley EJ, Chambers HF. Diabetic ketoacidosis precipitated by Staphylococcus aureus abscess and bacteremia due to acupuncture: case report and review of the literature. 2006. PMID: 16758409


  173. Chambers HF. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. 2006. PMID: 16524424


  174. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC,. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. 2005. PMID: 16231249


  175. Madrigal AG, Basuino L, Chambers HF. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. 2005. PMID: 16048918


  176. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for treatment of tuberculosis in mice and humans. 2005. PMID: 15980354


  177. Katayama Y, Robinson DA, Enright MC, Chambers HF. Genetic background affects stability of mecA in Staphylococcus aureus. 2005. PMID: 15872270


  178. Eguia JM, Liu C, Moore M, Wrone EM, Pont J, Gerberding JL, Chambers HF. Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area. 2005. PMID: 15889359


  179. Chambers HF. Community-associated MRSA--resistance and virulence converge. 2005. PMID: 15814886


  180. Siboo IR, Chambers HF, Sullam PM. Role of SraP, a Serine-Rich Surface Protein of Staphylococcus aureus, in binding to human platelets. Volume 73 of Issue 4. 2005. PMID: 15784571


  181. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. 2005. PMID: 15728879


  182. Winston LG, Charlebois ED, Pang S, Bangsberg DR, Perdreau-Remington F, Chambers HF. Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci. 2004. PMID: 15573053


  183. Young DM, Harris HW, Charlebois ED, Chambers H, Campbell A, Perdreau-Remington F, Lee C, Mankani M, Mackersie R, Schecter WP. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. 2004. PMID: 15381611


  184. Wilke MS, Hills TL, Zhang HZ, Chambers HF, Strynadka NC. Crystal structures of the Apo and penicillin-acylated forms of the BlaR1 beta-lactam sensor of Staphylococcus aureus. 2004. PMID: 15322076


  185. Charlebois ED, Perdreau-Remington F, Kreiswirth B, Bangsberg DR, Ciccarone D, Diep BA, Ng VL, Chansky K, Edlin BR, Edlin B, Chambers HF. Origins of community strains of methicillin-resistant Staphylococcus aureus. Volume 39 of Issue 1. 2004. PMID: 15206052


  186. Winston LG, Pang S, Haller BL, Wong M, Chambers HF, Perdreau-Remington F. API 20 strep identification system may incorrectly speciate enterococci with low level resistance to vancomycin. Volume 48 of Issue 4. 2004. PMID: 15062923


  187. Chambers HF, Winston LG. Mupirocin prophylaxis misses by a nose. 2004. PMID: 15023716


  188. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. 2004. PMID: 15034832


  189. Katayama Y, Zhang HZ, Chambers HF. PBP 2a mutations producing very-high-level resistance to beta-lactams. 2004. PMID: 14742194


  190. Eguia JM, Chambers HF. Community-acquired Methicillin-resistant Staphylococcus aureus: Epidemiology and Potential Virulence Factors. 2003. PMID: 14642185


  191. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. 2003. PMID: 14506006


  192. Katayama Y, Zhang HZ, Hong D, Chambers HF. Jumping the barrier to beta-lactam resistance in Staphylococcus aureus. 2003. PMID: 12949098


  193. Chambers HF. Solving staphylococcal resistance to beta-lactams. 2003. PMID: 12706985


  194. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. 2003. PMID: 12654656


  195. Eguia JM, Chambers HF. Methicillin-resistant staphylococci and their treatment in the intensive care unit. 2003. PMID: 16088523


  196. Katayama Y, Zhang HZ, Chambers HF. Effect of disruption of Staphylococcus aureus PBP4 gene on resistance to beta-lactam antibiotics. 2003. PMID: 15000739


  197. Winston LG, Bangsberg DR, Chambers HF, Felt SC, Rosen JI, Charlebois ED, Wong M, Steele L, Gerberding JL, Perdreau-Remington F. Epidemiology of vancomycin-resistant Enterococcus faecium under a selective isolation policy at an urban county hospital. 2002. PMID: 12410216


  198. Charlebois ED, Bangsberg DR, Moss NJ, Moore MR, Moss AR, Chambers HF, Perdreau-Remington F. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. 2002. PMID: 11797167


  199. Kanaya AM, Glidden DV, Chambers HF. Identifying pulmonary tuberculosis in patients with negative sputum smear results. 2001. PMID: 11502628


  200. Chambers HF. The changing epidemiology of Staphylococcus aureus? 2001. PMID: 11294701


  201. Chambers HF. Methicillin-resistant Staphylococcus aureus. Mechanisms of resistance and implications for treatment. 2001. PMID: 19667557


  202. Chambers HF, Xiang Q, Chow LL, Hackbarth C. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus. 1999. PMID: 10543757


  203. Martin JN, Perdreau-Remington F, Kartalija M, Pasi OG, Webb M, Gerberding JL, Chambers HF, Täuber MG, Lee BL. A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. 1999. PMID: 10438389


  204. Kim YS, Liu Q, Chow LL, Chambers HF, Täuber MG. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus. 1998. PMID: 9835540


  205. Sheppard DC, Chambers HF. Suppurative parotitis. 1998. PMID: 9735697


  206. Chambers HF, Kocagöz T, Sipit T, Turner J, Hopewell PC. Activity of amoxicillin/clavulanate in patients with tuberculosis. 1998. PMID: 9564467


  207. Hackbarth CJ, Unsal I, Chambers HF. Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra. 1997. PMID: 9145897


  208. Sweet-Cordero EA, Chambers HF, Cicero-Sabido R, Santos-Preciado JI. Burden of Mycobacterium tuberculosis in sputum samples can be reliably determined using a quantitative, non-radioactive polymerase chain reaction assay. 1996. PMID: 9039441


  209. Kocagöz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. 1996. PMID: 8843279


  210. Frank U, Chambers HF. Treatment of Staphylococcus aureus catheter-related infection and infective endocarditis with granulocyte colony-stimulating factor in the experimental rabbit model. 1996. PMID: 8723492


  211. Lee BL, Täuber MG, Sadler B, Goldstein D, Chambers HF. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. 1996. PMID: 8549029


  212. Chambers HF, Moreau D, Yajko D, Miick C, Wagner C, Hackbarth C, Kocagöz S, Rosenberg E, Hadley WK, Nikaido H. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? 1995. PMID: 8592990


  213. Yajko DM, Wagner C, Tevere VJ, Kocagöz T, Hadley WK, Chambers HF. Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and dilution endpoint of its detection by the Amplicor PCR assay. 1995. PMID: 7665679


  214. Chambers HF, Kartalija M, Sande M. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits. 1995. PMID: 7706817


  215. Chambers HF. In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a. 1995. PMID: 7726516


  216. Hackbarth CJ, Kocagoz T, Kocagoz S, Chambers HF. Point mutations in Staphylococcus aureus PBP 2 gene affect penicillin-binding kinetics and are associated with resistance. 1995. PMID: 7695289


  217. Hackbarth CJ, Miick C, Chambers HF. Altered production of penicillin-binding protein 2a can affect phenotypic expression of methicillin resistance in Staphylococcus aureus. 1994. PMID: 7872749


  218. Chambers HF, Fournier MA. Efficacy of cefoperazone in combination with sulbactam in experimental Staphylococcus aureus endocarditis in rabbits. 1993. PMID: 8262867


  219. Chambers HF. Detection of methicillin-resistant staphylococci. 1993. PMID: 8345177


  220. Hackbarth CJ, Chambers HF. blaI and blaR1 regulate beta-lactamase and PBP 2a production in methicillin-resistant Staphylococcus aureus. 1993. PMID: 8517704


  221. Chambers HF. Short-course combination and oral therapies of Staphylococcus aureus endocarditis. 1993. PMID: 8463654


  222. Chambers HF. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. 1992. PMID: 1399943


  223. Chambers HF, Miick C. Characterization of penicillin-binding protein 2 of Staphylococcus aureus: deacylation reaction and identification of two penicillin-binding peptides. 1992. PMID: 1622180


  224. Gerberding JL, Miick C, Liu HH, Chambers HF. Comparison of conventional susceptibility tests with direct detection of penicillin-binding protein 2a in borderline oxacillin-resistant strains of Staphylococcus aureus. 1991. PMID: 1810191


  225. Lee BL, Sachdeva M, Chambers HF. Effect of protein binding of daptomycin on MIC and antibacterial activity. 1991. PMID: 1667253


  226. Barg N, Chambers H, Kernodle D. Borderline susceptibility to antistaphylococcal penicillins is not conferred exclusively by the hyperproduction of beta-lactamase. 1991. PMID: 1759816


  227. Chambers HF. Treatment of infection and colonization caused by methicillin-resistant Staphylococcus aureus. 1991. PMID: 1847961


  228. Chambers HF, Sachdeva M, Kennedy S. Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. 1990. PMID: 2387996


  229. Stratton CW, Gelfand MS, Gerberding JL, Chambers HF. Characterization of mechanisms of resistance to beta-lactam antibiotics in methicillin-resistant strains of Staphylococcus saprophyticus. 1990. PMID: 2285290


  230. Chambers HF, Sachdeva M. Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. 1990. PMID: 2345297


  231. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. 1990. PMID: 2393284


  232. Chambers HF, Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. 1990. PMID: 2140496


  233. Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. 1989. PMID: 2572799


  234. Padula A, Chambers HF. Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits. 1989. PMID: 2686548


  235. Kennedy S, Chambers HF. Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. 1989. PMID: 2554799


  236. Hackbarth CJ, Chambers HF. Methicillin-resistant staphylococci: detection methods and treatment of infections. 1989. PMID: 2675760


  237. Hackbarth CJ, Chambers HF. Methicillin-resistant staphylococci: genetics and mechanisms of resistance. 1989. PMID: 2675759


  238. Chambers HF, Archer G, Matsuhashi M. Low-level methicillin resistance in strains of Staphylococcus aureus. 1989. PMID: 2729937


  239. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. 1988. PMID: 3421575


  240. Jacobson MA, Gellermann H, Chambers H. Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex. 1988. PMID: 3400693


  241. Chambers HF. Methicillin-resistant staphylococci. 1988. PMID: 3069195


  242. Chambers HF. Coagulase-negative staphylococci resistant to beta-lactam antibiotics in vivo produce penicillin-binding protein 2a. 1987. PMID: 3439802


  243. Chambers HF, Hackbarth CJ. Effect of NaCl and nafcillin on penicillin-binding protein 2a and heterogeneous expression of methicillin resistance in Staphylococcus aureus. 1987. PMID: 3439805


  244. Sachdeva M, Hackbarth C, Stella FB, Chambers HF. Comparative activity of CGP 31608, nafcillin, cefamandole, imipenem, and vancomycin against methicillin-susceptible and methicillin-resistant staphylococci. 1987. PMID: 3481245


  245. Chambers HF, Miller MH. Emergence of resistance to cephalothin and gentamicin during combination therapy for methicillin-resistant Staphylococcus aureus endocarditis in rabbits. 1987. PMID: 3643249


  246. Carpenter TC, Hackbarth CJ, Chambers HF, Sande MA. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus. 1986. PMID: 3640590


  247. Hackbarth CJ, Chambers HF, Sande MA. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. 1986. PMID: 3707110


  248. Chambers HF, Hartman BJ, Tomasz A. Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin. 1985. PMID: 4019783


  249. Sullam PM, Täuber MG, Hackbarth CJ, Chambers HF, Scott KG, Sande MA. Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus. 1985. PMID: 3860185


  250. Chambers HF, Mills J, Drake TA, Sande MA. Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. 1984. PMID: 6522927


  251. Chambers HF, Sande MA. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. 1984. PMID: 6236747


  252. Chambers HF, Hackbarth CJ, Drake TA, Rusnak MG, Sande MA. Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro. 1984. PMID: 6564133


  253. Chambers HF, Korzeniowski OM, Sande MA. Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts. 1983. PMID: 6843356


UCSF Sublogo

 
© 2025 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Medicine                                                                  Accessibility  Privacy Policy  Terms of Use  A-Z Website List